INIS Stock Overview
Manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, sodium iodide I-131 drug product, and radiochemicals for clinical research and life sciences in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
International Isotopes Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.038 |
| 52 Week High | US$0.055 |
| 52 Week Low | US$0.02 |
| Beta | 0.49 |
| 11 Month Change | 3.54% |
| 3 Month Change | 18.75% |
| 1 Year Change | -13.64% |
| 33 Year Change | -54.68% |
| 5 Year Change | -41.54% |
| Change since IPO | -99.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| INIS | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 18.0% | -5.8% | -1.0% |
| 1Y | -13.6% | 1.7% | 30.3% |
Return vs Industry: INIS underperformed the US Life Sciences industry which returned 1.2% over the past year.
Return vs Market: INIS underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| INIS volatility | |
|---|---|
| INIS Average Weekly Movement | 15.7% |
| Life Sciences Industry Average Movement | 8.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: INIS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: INIS's weekly volatility has decreased from 21% to 16% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 40 | Shahe Bagerdjian | www.intisoid.com |
International Isotopes Inc. manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, sodium iodide I-131 drug product, and radiochemicals for clinical research and life sciences in the United States and internationally. It operates through four segments: Nuclear Medicine Standards, Cobalt Products, Theranostics Products, and Fluorine Products. The Nuclear Medicine Standards segment manufactures sources and standards associated with single photon emission computed and positron emission tomography imaging, patient positioning, and calibration or operational testing of dose measuring equipment for the nuclear pharmacy industry.
International Isotopes Inc. Fundamentals Summary
| INIS fundamental statistics | |
|---|---|
| Market cap | US$17.28m |
| Earnings (TTM) | -US$346.30k |
| Revenue (TTM) | US$13.15m |
1.5x
P/S Ratio-57.5x
P/E RatioIs INIS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INIS income statement (TTM) | |
|---|---|
| Revenue | US$13.15m |
| Cost of Revenue | US$4.85m |
| Gross Profit | US$8.30m |
| Other Expenses | US$8.64m |
| Earnings | -US$346.30k |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.00066 |
| Gross Margin | 63.12% |
| Net Profit Margin | -2.63% |
| Debt/Equity Ratio | 148.3% |
How did INIS perform over the long term?
See historical performance and comparison